A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: Short- and long-term outcomes - 09/08/11
San Francisco, California, and New York, New York
Abstract |
Background |
The merit of topical sequential therapy involving clobetasol foam and calcipotriene ointment has not been experimentally demonstrated.
Objective |
We sought to assess the short-term efficacy of twice-daily clobetasol foam plus calcipotriene ointment compared with either agent alone as monotherapy and to compare long-term use of weekday calcipotriene ointment with or without clobetasol foam weekend pulse therapy.
Methods |
Eighty-six subjects with plaque-type psoriasis received twice-daily treatment with clobetasol foam plus calcipotriene ointment or either agent as monotherapy for 2 weeks. Subjects in the combination group who achieved remission received weekday calcipotriene plus weekend pulse therapy with either clobetasol foam or vehicle for 6 months.
Results |
After 2 weeks, psoriasis scores were significantly lower (P < .001) in the combination therapy group (adjusted trunk lesion score = 0.67) compared with monotherapy with either agent (lesion scores = 1.40 calcipotriene, 1.13 clobetasol foam). During the follow-up “weekday-weekend” phase, after 6 months, weekend pulse clobetasol foam was associated with a trend toward greater maintenance of remission compared with vehicle (92% improvement of trunk lesion vs 62%).
Limitations |
Small sample size may have hampered the detection of statistical significance during long-term therapy.
Conclusion |
The combination of clobetasol foam and calcipotriene ointment is significantly more effective than monotherapy for short-term treatment. Weekday calcipotriene plus weekend pulse clobetasol foam shows a consistent trend toward greater maintenance of remission.
Le texte complet de cet article est disponible en PDF.Plan
Supported by Connetics Corporation, Palo Alto, Calif. Disclosure: Dr Koo has been a clinical researcher and/or consultant and/or speaker for Allergan, Warner-Chilcott, Amgen, Biogen, Bristol-Myers Squibb, Centacor, Connetics, Elan, Astellas, Galderma, Genentech, GlaxoSmithKlein, Novartis, Roche, Serono and Valient. Dr Blum is an employee of the Department of Dermatology at Mount Sinai School of Medicine. Dr Lebwohl has been a clinical researcher and/or consultant and/or speaker for Abbot Laboratories, Allergan, Amgen, Astellas, Biogen Idec, Centecor, Connetics, Genentech, Novartis, Pharmaderm, Pfizer, Warner-Chilcott, and 3M. |
Vol 55 - N° 4
P. 637-641 - octobre 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?